Prognostic value of TP53, KRAS and EGFR mutations in nonsmall cell lung cancer: the EUELC cohort

C Scoccianti, A Vesin, G Martel… - European …, 2012 - Eur Respiratory Soc
Nonsmall cell lung cancer samples from the European Early Lung Cancer biobank were
analysed to assess the prognostic significance of mutations in the TP53, KRAS and EGFR …

Distinct pattern of TP53 mutations in squamous cell carcinoma of the esophagus in Iran

A Sepehr, P Tanière, G Martel-Planche, AA Zia'ee… - Oncogene, 2001 - nature.com
Extremely high rates of squamous cell carcinoma of the esophagus (SCCE) are observed in
Iran, reflecting unknown, genetic and/or epidemiological risk factors. Among genetic …

Interactions between hepatitis B virus and aflatoxin B1: effects on p53 induction in HepaRG cells

…, P Berthillon, G Martel-Planche… - Journal of general …, 2012 - microbiologyresearch.org
Infection by hepatitis B virus (HBV) and dietary exposure to aflatoxin B 1 (AFB 1 ) are the
main risk factors for the development of chronic liver disease and hepatocellular carcinoma (…

Molecular and clinical differences between adenocarcinomas of the esophagus and of the gastric cardia

P Tanière, G Martel-Planche, D Maurici… - The American journal of …, 2001 - Elsevier
Adenocarcinoma of the esophagus (ADCE) with Barrett’s mucosa and adenocarcinoma of
the cardia (ADCC) are often reported as a single pathological entity. In this study we have …

[HTML][HTML] TP53 mutations, human papilloma virus DNA and inflammation markers in esophageal squamous cell carcinoma from the Rift Valley, a high-incidence area …

…, T Gheit, M Tommasino, G Martel-Planche… - BMC research …, 2011 - Springer
Background Squamous Cell Carcinoma of Esophagus is one of the most common
malignancies in both men and women in eastern and south-eastern Africa. In Kenya, clinical …

Mutation of TP53 and alteration of p14arf expression in EGFR-and KRAS-mutated lung adenocarcinomas

AB Cortot, M Younes, G Martel-Planche, B Guibert… - Clinical lung cancer, 2014 - Elsevier
Background In lung adenocarcinoma, inactivation of the tumor suppressor p53 may abrogate
a safeguard mechanism preventing the development of tumors with activating mutations in …

[PDF][PDF] Prevalence and prognostic value of TP53 KRAS and EGFR mutations in the EUELC cohort

G Martel, M Olivier, P Hainaut - academia.edu
Field, John; Roy Castle Lung Cancer Research Programme, The University of Liverpool Cancer
Research Centre, Institute of Translational Medicine, The University of Liverpool Hainaut…

Erratum: Distinct pattern of TP53 mutations in squamous cell carcinoma of the esophagus in Iran

A Sepehr, P Tanière, G Martel-Planche, AA Zia'ee… - Oncogene, 2002 - nature.com
Extremely high rates of squamous cell carcinoma of the esophagus (SCCE) are observed in
Iran, reflecting unknown, genetic and/or epidemiological risk factors. Among genetic …

[PDF][PDF] Évolution de l'incidence du cancer du foie à Bamako, Mali

M de Seze - academia.edu
Le Carcinome Hepato Cellulaire (CHC) est un cancer du foie hautement répandu dans le
monde, en particulier dans les régions à faibles ressources comme l'Afrique de l'Ouest. …

Etude des relations entre les mutations EGFR/KRAS et les altérations de la voie p53/p14arf et caractérisation d'une nouvelle cible thérapeutique, le complexe …

M Younes - 2012 - theses.hal.science
Nous avons étudié, le statut de la voie p53/p14arf dans l'adénocarcinome bronchique muté
pour EGFR ou KRAS ainsi que l'impact du complexe NTS/NTSR1 sur la progression …